Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3,962 CHF | +0.92% | +0.28% | +13.72% |
Apr. 25 | Dpa-AFX Overview: COMPANIES from 25.04.2024 - 15:15 | DP |
Apr. 25 | Symrise disappoints despite strong sales growth | DP |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
- The company has a good ESG score relative to its sector, according to Refinitiv.
Strengths
- The company returns high margins, thereby supporting business profitability.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- The company is in debt and has limited leeway for investment
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 37.33 times its estimated earnings per share for the ongoing year.
- The company's "enterprise value to sales" ratio is among the highest in the world.
- The company appears highly valued given the size of its balance sheet.
- The company is highly valued given the cash flows generated by its activity.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Over the past twelve months, analysts' opinions have been revised negatively.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+13.72% | 39.97B | B+ | ||
+11.47% | 63.22B | A- | ||
-3.47% | 46.34B | A- | ||
+17.83% | 25.46B | A- | ||
+7.27% | 18.68B | C+ | ||
-0.57% | 17.24B | B+ | ||
-21.73% | 15.81B | A- | ||
+0.22% | 14.9B | B+ | ||
-19.10% | 13.74B | C+ | ||
+35.12% | 12.81B | A- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GIVN Stock
- Ratings Givaudan SA